Drug Hunter - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Drug Hunter

Drug Hunter

Publication
0 followers

Blog highlighting medicinal chemistry and drug discovery breakthroughs, mechanisms, and industry trends, authored by a pharmaceutical chemist

Recent Posts

Module 2, Section 2: The Druggable Interactome
News•Mar 2, 2026

Module 2, Section 2: The Druggable Interactome

The Module 2, Section 2 lecture introduces the druggable interactome, compiling key resources that map the human druggable genome, protein expression, kinase families, transcription‑factor proteomics, GPCRs, and ion‑channel complexes. It highlights quantitative estimates—over 3,000 proteins deemed druggable and hundreds of actionable kinases—while linking these datasets to disease relevance. The slide deck cites seminal literature that underpins current target‑identification strategies and points to emerging analytical methods for deeper interactome coverage. Together, these references form a roadmap for systematic target discovery across multiple protein families.

By Drug Hunter
January 2026 Patent Highlights
News•Feb 26, 2026

January 2026 Patent Highlights

The January 2026 Patent Highlights roundup spotlights a wave of new intellectual‑property activity across several cutting‑edge drug discovery areas. Notable filings include lysine‑directed covalent inhibitor chemotypes, strategies to balance potency with drug‑like properties, refined target‑selection frameworks, dozens of Polθ synthetic‑lethal patents...

By Drug Hunter
Dotinurad (FYU-981)
News•Feb 25, 2026

Dotinurad (FYU-981)

Dotinurad (FYU‑981), marketed as Urece®, is a URAT1 inhibitor approved for gout and hyperuricemia in Japan and China. The drug was chemically refined from the older uricosuric benzbromarone to retain potency while eliminating rare hepatotoxic events. Crystalys Therapeutics is now...

By Drug Hunter
Karma-Karma-Karma Chameleon
News•Feb 23, 2026

Karma-Karma-Karma Chameleon

Balancing potency with oral bioavailability remains a core hurdle as drug candidates grow larger and more complex. Researchers now focus on "chameleonicity"—the ability of a molecule to toggle between polar and lipophilic conformations—to reconcile solubility and permeability. The article outlines...

By Drug Hunter
Module 2, Section 1: Target Selection Strategy
News•Feb 23, 2026

Module 2, Section 1: Target Selection Strategy

The module outlines a five‑dimensional framework for target selection, linking biological relevance, drugability, disease impact, competitive landscape, and development risk. It contrasts first‑in‑class and best‑in‑class strategies, highlighting how pioneering mechanisms can command premium market positions. The content identifies oncology as...

By Drug Hunter
Tradipitant
News•Feb 19, 2026

Tradipitant

Vanda Pharmaceuticals received FDA approval for tradipitant (Nereus®), an oral selective NK1 receptor antagonist, to treat motion‑induced nausea and vomiting. The approval marks the first new drug for motion sickness in more than four decades, highlighting a significant regulatory milestone....

By Drug Hunter
Aceclidine
News•Feb 18, 2026

Aceclidine

Aceclidine (Vizz®) received FDA approval in 2025 as an ophthalmic solution for presbyopia, targeting age‑related near‑vision loss. The drug acts as a pupil‑selective muscarinic agonist, inducing miosis without significant ciliary muscle activity, thereby enhancing depth of focus through a pinhole...

By Drug Hunter
Safer CNS Drugs with BrainOnly Pharmacology
News•Feb 17, 2026

Safer CNS Drugs with BrainOnly Pharmacology

The article outlines a growing strategy to develop central nervous system (CNS) therapeutics that remain pharmacologically active only within the brain, termed "BrainOnly" pharmacology. By leveraging selective transport mechanisms, pro‑drug designs, and peripheral clearance pathways, researchers aim to minimize off‑target...

By Drug Hunter
Making a MASH Hit: PNPLA3 and the Rise of Genotype-Driven Therapies
News•Feb 16, 2026

Making a MASH Hit: PNPLA3 and the Rise of Genotype-Driven Therapies

The lipid serine hydrolase PNPLA3, especially its I148M mutant, has emerged as a genetically validated driver of MASLD/MASH, prompting a wave of genotype‑focused drug programs. RNA‑based modalities—Arrowhead’s GalNAc‑siRNA ARO‑PNPLA3 and AstraZeneca/Ionis’ GalNAc‑ASO AZD2693—are in clinical trials aiming to lower mutant...

By Drug Hunter
Vimseltinib
News•Feb 10, 2026

Vimseltinib

Deciphera Pharmaceuticals received FDA approval for vimseltinib, an oral, selective CSF1R kinase inhibitor, to treat tenosynovial giant cell tumor (TGCT). The drug emerged from structure‑based drug design (SBDD) and extensive SAR optimization, as reported in Bioorganic & Medicinal Chemistry Letters...

By Drug Hunter
The New WIZ-Kid in Protein Degradation
News•Feb 9, 2026

The New WIZ-Kid in Protein Degradation

Targeted protein degraders that eliminate the transcription factors WIZ and ZBTB7A are shown to raise fetal hemoglobin (HbF) levels, offering a disease-modifying strategy for sickle cell disease and β‑thalassemia. Novartis disclosed a series of CRBN‑based glue degraders, culminating in the...

By Drug Hunter
Module 1 Quiz
News•Feb 9, 2026

Module 1 Quiz

Drug Hunter has launched a Module 1 Quiz to evaluate learners’ grasp of introductory drug‑discovery concepts. The quiz spans all sections of the first module and is accessible through the platform’s subscription model. Users can take the assessment after reviewing the...

By Drug Hunter
Identification Methods for Drug Repurposing: Case Studies in Neurodegeneration
News•Feb 6, 2026

Identification Methods for Drug Repurposing: Case Studies in Neurodegeneration

The article outlines modern methods for identifying drug repurposing opportunities, focusing on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. It highlights computational screening, network pharmacology, and real‑world evidence as core techniques, and presents case studies where existing drugs showed disease‑modifying...

By Drug Hunter
It Takes Multiple to Mambo
News•Feb 2, 2026

It Takes Multiple to Mambo

Recent disclosures illustrate how multimeric design is reshaping drug discovery in the beyond‑Rule‑of‑5 (bRo5) space. GSK’s dimeric BET inhibitor GSK785 uses a rigid diazaspiro linker to achieve >30‑fold BRD4 selectivity, while Eli Lilly’s muvalaplin dimer‑to‑trimer architecture delivers a 10,000‑fold potency boost...

By Drug Hunter
Section 4: The All-Important Dose
News•Feb 2, 2026

Section 4: The All-Important Dose

The blog post emphasizes dose as a pivotal factor distinguishing first‑in‑class from next‑generation therapeutics. It links total dose and dosing regimen to core drug attributes such as potency, pharmacokinetics, and safety. The discussion covers route of administration, dosing schedules, and...

By Drug Hunter

Page 1 of 2

12Next →